ABLI — Abliva AB Share News
0.000.00%
Last trade - 00:00- SEK467.94m
- SEK435.27m
Brief: Neurovive Pharmaceutical Q3 pre-tax loss narrows to SEK 13.2 mln
Refile: BRIEF-Neurovive says clinical development project KL1333 gets positive opinion on European orphan drug designation
Brief: NeuroVive Pharmaceutical appoints David Laskow-Pooley new chairman
Brief: Neurovive Pharmaceutical carries out new issue of SEK 5.3 mln
Brief: NeuroVive signs collaboration agreement with University of Florida
Brief: Neurovive and Lund university receive grant for liver cancer research
Brief: Neurovive: the Children's Hospital of Philadelphia awarded NIH grant
Brief: Neurovive Pharmaceutical Q2 loss before tax 22 mln SEK
Brief: NeuroVive signs private placement agreement with Esousa Holdings LLC and issues units
Brief: NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm
Brief: NeuroVive enters research agreements in NASH and hepatocellular carcinoma
Brief: Neurovive Q4 pretax loss doubles yr/yr
Brief: Neurovive preclinical data shows substances have inhibitory effect on liver cancer
Brief: Neurovive redirects research resources from Asian subsidiary to parent company
Brief: Neurovive signs mitochondrial medicine research agreement with Philadelphia hospital
Brief: Neurovive signs collaboration agreement with Karolinska Institutet
Brief: A1M Pharma: Mitochondrial protective effect of rA1M in preclinical studies
Brief: Neurovive Pharmaceutical Q3 loss before tax 34.3 mln SEK
Brief: Neurovive reports positive pre-clinical results for NVP018